QUANTITATIVE AND ELECTROPHORETIC ANALYSIS OF COLLAGEN IN CULTURED FIBROBLASTS OF TWO PATIENTS WITH A MILD TYPE I OF OSTEOGENESIS IMPERFECTA DURING TREATMENT WITH BISPHOSPHONATES
Kocova M1,*, Galicka A2, Woczyñski S3, Sukarova-Angelovska E1, Stefanovska I4
*Corresponding Author: Professor Dr. Mirjana Kocova, Pediatric Clinic, Faculty of Medicine, Vodnjanska 17, 1000 Skopje, Republic of Macedonia; Tel: +389-2-3111-713; Fax: +389-2-3176-167; E-mail: ozonunit@unet. com.mk
page: 13

RESULTS AND DISCUSSION

All fractures in P1 and P2 before introduction of ther­apy were treated conservatively. The clinical, laboratory and X- ray data are summarized in Table 1. There was an extremely good response to the therapy. After 2 months of therapy the parents of both children noticed that they be­came more active, probably because of the decrease of pain in the bones. After 26 and 18 months of therapy, respectively, neither patient had incurred any additional fractures, despite normal physical activity. Serum alkaline phosphatase activity decreased, and OSI was within nor­mal range for the age.

Cultured skin fibroblasts of patients and control syn­thesized and secreted types I and III procollagens as shown in Fig. 1(A). However, in control fibroblasts, type III pro­collagen accounted for 5-7% of total collagen, whereas in the patients the levels of type III and type I procollagens were comparable. This may mean increased synthesis of type III or decreased synthesis of type I procollagen. In the type I OI, increased ratio of type III to type I procollagen usually results from half normal amount of type I pro­collagen caused by one "null" allele of COL1A1 gene encoding the proa1(I) chain, while the level of type III procollagen is normal [14]. However, collagen biosyn­thesis, measured by [3H]proline incorporation into proteins susceptible to the action of bacterial collagenase, in cells from both patients was comparable to the control (Fig. 2). When we loaded onto each slab the same amount of radio­activity incorporated into collagen, we noted a decreased level of type I collagen in OI fibroblasts with respect to control [Fig. 1(B)], while the level of type III collagen was markedly increased. If only normal collagen is produced by cells from our patients but in reduced amounts as in type I OI, the increased proportion of type III collagen may be a compensatory response to the low production of type I collagen. However, the control cells secreted about 50% of total collagen into the medium, whereas fibroblasts from the OI patients secreted less than the control by ap­proximately 19 and 28%, respectively (Fig. 3). In addi­tion, the amount of intracellular collagen increased in OI cells relative to the control fibroblasts. Secretion of non collagenous protein by the OI cells is also less efficient than by the control, which may suggest a more generalized transport defect in OI cells. However, in contrast to the control, the level of secreted collagen in OI medium is lower than that of non collagenous protein. This may indi­cate the presence of mutated collagen in cells and delayed secretion. The marker of mutated collagen is usually de­layed electrophoretic migration of procollagen and/or collagen chains caused by their over modification [4,5], although a normal migration does not exclude the presence of structurally abnormal collagen. In both patients migra­tion of secreted procollagen and collagen chains did not differ markedly from the control (Fig. 1). Faster migrating bands under a2(I) chains [Fig. 1(B)] were present in me­dium from both patients and control, but absent in the cell layers. To identify a molecular defect, analysis of DNA is needed.

 

 

 

Figure 1. Sodium dodecyl sulphate (SDS)/polyacrylamide gel electrophoresis (PAGE) of procollagen (A) and collagen (B), synthesized and secreted into medium by the control (C) and OI patients’ (P1, P2) fibroblasts. Procollagens were separated in reducing, and collagens in non reducing conditions. Migration of procollagen and collagen chains and of fibronectin (FN) are indicated.

 

 

Figure 2. Collagen biosynthesis in the control (C) and patients’ (P1, P2) fibroblasts. Results are shown as combined values for cell plus medium fractions. Each value represents the mean for four independent experiments (repeated at different times from different passages of cells). The results were submitted to statistical analysis using the Student’s t-test, accepting p<0.05 as significant.

 

 

 

 

Figure 3. Distribution of collagen and non collagenous proteins in medium and cell layer. Results are shown as percent of total collagen (i.e., cells plus medium). Dotted bars show collagen and clear bars non collagenous proteins. Each value represents the mean for four independent experiments (repeated at different times from different passages of cells). The results were submitted to statistical analysis using the Student’s t-test, accepting p<0.05 as significant.

 

Clinically, both our patients had type I OI. Since in these patients the collagen level is reduced, but has normal structure, the aim of therapy is to increase biosynthesis of collagen. Our results that after 9 and 20 months of ther­apy, respectively, the level of synthesized collagen was comparable with the control. This finding can be a result of increased biosynthesis of collage III in the patients. However, the mechanism of this increase is not known. The therapy may have caused the increase of collagen through the influence of gene expression, or through acti­vation of compensatory mechanisms. Therefore, the follow-up of collagen metabolism, before and during ther­apy with bisphosphonates, might be important in elucidat­ing drug-gene interactions in patients with OI.

 

Table 1. Clinical data, laboratory and X-ray findings

 

 

Clinical information

 

P1 (F-5.5)

 

P2 (M-3.5)

 

Family history

 

No other members affected

 

No other members affected

 

Age when the child started walking alone

 

14 months

 

17 months

 

First fracture

 

4 years

 

2.5 years

 

Number of fractures during the last year before diagnosis

 

3

 

3

 

Bones fractured

 

Right tibia twice; right femur

 

Right and left tibia; right femur

 

Blue sclera

 

[++]

 

[++]

 

Dentinogenesis imperfecta

 

[+]

 

[–]

 

Stature

 

75‰

 

50‰

 

X-ray of limbs

 

OI

 

OI

 

Ultrasound of kidneys

 

Normal

 

Normal

 

Alkaline phosphatase (range: 63-82 U/L)

 

229 U/L

 

208 U/L

 

Osteo-Sono assessment Index (OSI)

 

<2SD

 

<2SD

 

Clinical diagnosis

 

OI type I

 

OI type I

 

There are few data concerning the needed duration of bisphosphonate therapy in OI. More studies of collagen metabolism in different types of OI during therapy are needed in order to set up guidelines for the duration of the bisphosphonate therapy.

 




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006